Genervon Successfully Completes Its Phase 2a Clinical Trial For ALS
4/28/2014 11:14:58 AM
PASADENA, Calif--(BUSINESS WIRE)--Genervon Biopharmaceuticals LLC (“Genervon”) today announced that it has successfully completed its Phase 2a clinical trial for amyotrophic lateral sclerosis (“ALS”) disease modification. A full analysis of the trial’s results is expected to be completed in the third quarter of 2014, but preliminary data suggests that Genervon’s novel, proprietary, multi-target biological drug candidate, GM604, shows significant promise for treating ALS.
Help employers find you! Check out all the jobs and post your resume.
comments powered by